Meconium aspiration injures a number of cell types in the lung, most notably airway and alveolar epithelial lining cells. Recent data show that at least some of the cell death induced by meconium occurs by apoptosis, and therefore has the potential for pharmacologic inhibition through the use of apoptosis blockers or other strategies. Related work in adult animal models of lung injury has shown that apoptosis of lung epithelial cells induces a local (that is, entirely lung tissue specific) renin-angiotensin system (RAS L ). Furthermore, this inducible RAS L is required for the apoptotic response and affects other adjacent cell types through the release of angiotensin II and related peptides. This manuscript reviews the published data supporting this viewpoint as well as more recent works that suggest the involvement of a RAS L in the perinatal lung damage associated with meconium aspiration syndrome (MAS). The implications of these findings regarding their potential for the clinical management of MAS are also discussed.
General mechanisms in apoptosis Apoptosis, sometimes referred to as programmed cell death (PCD) or 'cell suicide', is a metabolically active process of cellular dismantling. Apoptosis avoids the inflammation often associated with necrotic cell death because cellular contents are often not released from apoptotic cells as they are from necrotic cells. A variety of cellular signaling pathways regulates apoptosis, which is characterized morphologically by nuclear fragmentation, cleavage of chromosomal DNA into internucleosomal fragments, packaging of cellular debris into 'apoptotic bodies' without plasma membrane breakdown and exposure of surface molecules targeting the cell remnants for phagocytosis. 1, 2 Major signaling pathways leading to apoptosis involve the activation of cystein-dependent, aspartate-directed proteases termed caspases. Depending on the type of stimuli and/or cell type, the apoptotic cascade can follow either an intrinsic pathway, involving apoptogenic mitochondrial proteins such as cytochrome c, or an extrinsic pathway that follows activation of a death receptor. The receptor is usually activated by its extracellular ligand, such as the binding of Fas ligand (FasL) to Fas (APO-1 or CD95) or tumor necrosis factor-a (TNF-a) binding to TNF-a receptor. On activation, initiator caspases (caspase-2, -8, -9, and -10) propagate death signals by activating downstream effector caspases (caspase-3, -6, and -7) in a cascade-like manner. Activated effector caspases mediate the release of caspase-activated DNase (CAD) from the complex with its endogenous inhibitor (ICAD) through a proteolytic cleavage. The activated CAD then cleaves genomic DNA between nucleosomes to generate DNA fragments, which are multiples of 180 to 200 bp in length. These fragments can form the 'DNA ladder' pattern seen on elecrophoresis, a frequently used marker of apoptosis.
Caspase-independent mechanisms of apoptosis are mediated by mitochondrial effectors; in this pathway, poly(ADP-ribose) polymerase-1-mediated DNA damage is signaled to mitochondria. This leads to release and translocation of apoptosis-inducing factor (AIF) from the mitochondria to the nucleus. AIF enhances endonuclease activity through its cooperation with endonuclease G or cyclophilin A, which leads to large-scale DNA fragmentation and chromatin condensation.
In contrast to apoptosis, which requires energy in the form of ATP, necrosis is the end result of a bioenergetic catastrophe resulting from ATP depletion to a level incompatible with cell survival. Cells that die by necrosis frequently exhibit changes in plasma membrane and nuclear morphology but not the organized chromatin condensation or DNA laddering that are characteristic of apoptosis.
1 Necrosis-like PCD, or autophagy, is also considered as alternative PCD that is caspase independent. Autophagy features degradation of cellular components within the intact dying cell in autophagic vacuoles that undergoes phagocytosis. Autophagic cells exhibit vacuolization, degradation of cytoplasmic contents and slight chromatin condensation; the molecular mechanisms regulating autophagy are now being elucidated.
2,3
Mechanisms of apoptosis specific to the lungs The topic of apoptosis and its regulation in the lungs has been reviewed recently;
4 this section will briefly summarize apoptosis mechanisms specific to acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis (PF) that may be relevant to meconium aspiration syndrome (MAS). Apoptosis of epithelial cells, neutrophils and endothelial cells are all thought to play roles in ARDS. The Fas-FasL system is thought to play a role in epithelial apoptosis in ARDS on the basis that bronchoalveolar lavage (BAL) fluids obtained from ARDS patients contain soluble Fas and FasL and induce apoptosis in lung epithelial cell line. [5] [6] [7] [8] Involvement of BAX, a homolog of Bcl-2 and its likely proapoptotic effect on type II pneumocytes was suggested in studies of diffuse alveolar damage.
9,10 Neutrophils were found to accumulate at inflammatory sites in the lung, in pulmonary edema fluid and BAL fluid from patients with ARDS.
11 This accumulation is due in part to delayed neutrophil apoptosis,; in addition, apoptosis of epithelial cells is enhanced at the same site.
12-14 BAL fluids from patients with ARDS had elevated levels of granulocyte/macrophage colony-stimulating factor that inhibits neutophil apoptosis through phosphoinositide 3-kinase and ERK pathway 15, 16 and stabilizes the factor Mcl-1 that is crucial for the delay of apoptosis initiated by antiapoptotic factors. 17, 18 BAL fluids from patients with ARDS was also cytotoxic to lung microvascular endothelial cells due to the presence of TNF-a and angiostatin, an inhibitor of angiogenesis in vivo. 19, 20 Furthermore, apoptosis signal-regulating kinase (ASK)-1 was involved in apoptosis of pulmonary vascular endothelial cells challenged with H 2 O 2 .
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Given the known roles of H 2 O 2 generated by activated neutrophils and other phagocytes, this suggests the possibility that inhibitors of ASK-1 and its signaling pathway might have potential benefit in the management of ARDS.
Cell death by apoptosis is likely an important contributor to the pathogenesis of COPD. Apoptosis of both inflammatory and alveolar wall cells in emphysema was reported by several research groups. [22] [23] [24] [25] Induction of apoptosis by active caspase-3 instillation in mice caused architectural changes in the lungs similar to those observed in human emphysema. 26 Oxidant stress, such as that resulting from cigarette smoke, results in the killing of lung cells by both apoptosis and necrosis. Glutathione S-transferase was shown to have a protective effect on tobacco smoke-induced apoptosis. 27, 28 Other studies have implicated endogenous growth factors and cytokines in COPD-associated apoptosis. One example is vascular endothelial growth factor (VGEF); decreased VGEF expression or blockade of VGEF receptors caused emphysematous changes in lung architecture. 29, 30 Another group of endogenous mediators believed to play role in apoptosis of parenchymal cells of the lung in COPD is TNF-a, FasL and Fas. However, it is unclear at present whether these molecules are elevated or contribute to the severity of COPD [31] [32] [33] and more work is needed to clarify these issues. Recent studies support the notion that apoptosis contributes to the pathogenesis of lung fibrosis as well as to its resolution. Many studies strongly suggest a role of epithelial apoptosis as a key profibrotic event in lung fibrogenesis. Apoptosis of alveolar epithelial cells (AECs) is found in patients with idiopathic PF (IPF) and in animal models of the disease. [34] [35] [36] The epithelial apoptosis colocalizes with myofibroblasts where collagen deposition is severe. 37 Blockade of apoptosis by either the angiotensin-converting enzyme (ACE) inhibitor captopril, caspase inhibition or the forced expression of p21 in lung epithelial cells exerted antifibrotic effects in animal models. 36, 38, 39 Together, these data suggested that the fibrotic response is secondary to the apoptotic death of epithelial cells in the lung. The death receptor Fas was found to be expressed in AECs within the lungs of IPF patients and circulating levels of its ligand FasL correlated with disease activity. [40] [41] [42] Similar observations were observed in animal models. 43, 44 Activation of Fas-induced apoptosis of bronchial and AECs is sufficient to initiate a fibrotic response in animal models. 43 However, development of bronchiolar and alveolar epithelial apoptosis and fibrosis in the lungs of Fas-null mice was similar to wild-type mice, 45, 46 which suggests that other pathways different from Fas can initiate epithelial apoptosis and facilitate fibrogenesis. Other works have suggested the involvement of c-Jun N-terminal kinase and p38, members of the mitogen-activated protein kinases family pathways in the signaling of epithelial apoptosis. 46, 47 Finally, several lines of evidence have shown that the angiotensin system plays a critical role in AECs apoptosis and in lung fibrogenesis, and these will be discussed next.
The endocrine RAS versus local tissue RASes
In the classical or 'endocrine' RAS described many years ago, the 58 kDa precursor protein angiotensinogen (AGT) is synthesized primarily by the liver and is secreted into the circulation, where it is proteolytically cleaved by the kidney-derived aspartyl protease renin to yield the 10 amino-acid peptide angiotensin I (ANGI). ANGI travels through the vasculature and on entry into the pulmonary vascular bed, is cleaved by the dipeptidyl carboxypeptidase ACE to yield the eight amino-acid peptide angiotensin II (ANGII). ANGII then travels through the blood and elicits a number of endocrine functions including the release of aldosterone from the adrenals and contraction of vascular smooth muscle throughout a variety of vascular beds. 48 More recently described local RASes, which occur in virtually ever organ and tissue in which their presence has been evaluated, are classified as 'extrinsic' or 'intrinsic' depending on the origin of RAS system components. In extrinsic local RASes (RAS L [ext] ), such as is believed to occur in the heart, 49 one or more of the RAS components are synthesized locally but others are derived from the endocrine RAS. In intrinsic local RASes (RAS L [int] ), all of the components of a functional RAS are synthesized locally. In many local organ systems the term 'RAS' is a misnomer because often renin is not expressed locally but other aspartyl proteases such as cathepsin D can accomplish the same proteolytic conversion of AGT to ANGI; moreover, other dipeptidyl carboxypeptidases such as chymase can cleave ANGI to ANGII. For this reason, many tissues have 'ACE-independent' pathways of ANGII formation that may not be affected by specific ACE inhibitors. Regardless, most tissues exhibit some degree of expression of the major ANGII receptor subtypes AT1 and AT2, either at baseline or after injury, which often upregulates one or both of these receptors. 50 The role of RASes in lung injury and fibrogenesis A wealth of literature supports the ability of ACE inhibitors or ANG receptor blockers to attentuate experimental lung cell death and fibrogenesis. The prototype ACE inhibitors captopril or lisinopril attenuated experimental lung fibrosis induced by monocrotaline, 51 bleomycin 52 or paraquat; 53 the ACE inhibitors also were found to be potent inhibitors of bleomycin-or TNF-a-induced apoptosis of lung epithelial cells. 54, 55 The ANG receptor AT1 antagonists losartan or candesartan have been shown to prevent lung fibrosis in response to radiation 56 or bleomycin, 57, 58 and also blocked apoptosis of lung alveolar epithelial cells in response to bleomycin 57 or the antiarrhythmic agent amiodarone. 59 Given the central role of epithelial cells death in lung injury in a variety of disease states, attention as been focused on defining the role of ANGII in apoptosis of lung alveolar epithelials (AECs).
In cell culture studies, ANGII itself was found to be a potent inducer of apoptosis in both the human AEC cell line A549 and in primary AECs isolated from adult rats. 60 The EC50s for ANGII-induced apoptosis in these cells (50 and 10 nM, respectively) are far above the concentrations of ANGII found in the circulation (B1 to 10 pM), even in severe hypertension, 48 which provides an explanation of why circulating ANGII does not kill AECs as it passes through the lungs. Although the cultured AECs expressed both the AT1 and AT2 ANG receptor subtypes, only AT1-selective antagonists could prevent ANGII-induced apoptosis. 61 Subsequent studies found that when cultured AECs are exposed to other inducers of apoptosis, they begin to synthesize their own ANGII de novo, that is, from the precursor AGT. The apoptosis inducers Fas ligand, 62 TNF-a, 55 bleomycin 54 and amiodarone 63 all induce expression of the gene for AGT in AECs at the level of AGT transcription, and cause a significant increase in the steady-state level of AGT mRNA. Moreover, AECs express all the enzymes necessary for conversion of AGT to the mature peptide ANGII, including ACE 62 and the aspartyl protease cathepsin D. 64 Thus, the alveolar epithelial cell expresses its own intrinsic local RAS in response to a variety of apoptosis inducers.
Further work showed that the expression of this local RAS and the generation of ANGII by AECs are required for AEC apoptosis in response to FAS ligand, TNF-a, bleomycin or amiodarone. In all those cases, AEC apoptosis in response to the inducer could be blocked by either ANG receptor blockers, 55 ,62 ACE inhibitors 54, 55 or by antisense oligonucleotides against AGT mRNA. 54,55,62 Therefore, not only do AECs produce ANGII in response to apoptosis inducers, but the ANGII production is an essential component of the apoptotic response and blockade of ANGII production or receptor interaction can block the cell death. Recent studies of human lung biopsies from patients with IPF have found double labeling of ANG peptides and markers of apoptosis in AECs; 65 these data support the notion that ANG peptide synthesis occurs in apoptotic AECs in the intact injured human lung as well as in animal models and cultured cells.
The role of RAS in MAS and potential for pharmacologic control Apoptotic AECs have been observed in several models of experimental MAS. 66, 67 Interest therefore was turned to the possibility that AECs dying in response to meconium might also require the local intrinsic RAS for their death and might be prevented from dying by ACE inhibitors of ANG receptor blockers. Several lines of investigation support the theory that meconium does indeed induce expression of the local RAS that might be amenable to pharmacologic blockade. Pretreatment of 2-week-old rabbit pups with the ACE inhibitor captopril before intratracheal instillation of human meconium prevented both meconium-induced upregulation of interleukin (IL)-6 and IL-8 and also reduced lung epithelial cell apoptosis detected by DNA fragmentation assay. 68 The captopril also appeared to reduced meconium-induced upregulation of AGT mRNA.
In a similar study of rats, Lukkarinen et al. 69 showed that pretreatement of rats with the nonselective ANG receptor blocker saralasin, given intraperitoneally before meconium instillation, prevented AEC apoptosis detected by both DNA fragmentation assay and electron microscopy. The meconium increase AGT mRNA in the lungs, suggesting apoptosis-induced upregulation of AGT in AECs. The saralasin also reduced meconium-induced upregulation of endothelial monocyte-activating polypeptide (EMAP-II) and total lung neutrophil accumulation, but had little effect on the increased wet/dry weight ratio induced by the meconium. The saralasin also had a small but statistically insignificant ability to reverse altered arterial blood gases.
Although not statistically significant, this latter result suggests that further refinement of dosing or route of administration might offer improvement of lung function, especially if more potent and selective ANGII antagonists (AT1 receptor-selective) or intratracheal administrations are explored. Regardless, all the data taken together strongly suggest that meconium, like other inducers of AEC apoptosis and lung injury, elicits the expression of the local RAS in AECs and that the RAS is intimately involved in their demise. Given the many agents already in clinical use for the manipulation of the RAS, it is proposed that further exploration of antagonists of the RAS and creative approaches to their application (for example, aerosols) may offer clinically useful adjuncts to the current pharmacotherapy of MAS in the future.
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